Blood-based biomarkers in patients with recurrent, persistent, or metastatic endometrial cancer treated with olaparib and cediranib: Results from NRG-GY012.
Andrew B Nixon, Danielle M Enserro, David P Bender et al.
✦ AI-curated · Sources linked
In 30 seconds
This biomarker analysis of the phase 2 NRG-GY012 clinical trial assessed blood-based markers and outcomes among patients with recurrent, persistent, or metastatic endometrial cancer treated with olaparib, cediranib, or both. Of 120 trial participants, 96 had baseline plasma samples analyzed. The previously reported IL-6 threshold of 2.9 pg/mL did not validate; using a 4.2 pg/mL median cut point, higher IL-6 was associated with worse prognosis but potentially greater overall-survival benefit in cediranib arms (interaction p = .085). OPN and PlGF also showed potential treatment-predictive associations.
Key findings
- The GOG-218 IL-6 threshold of 2.9 pg/mL did not validate in this analysis; at a 4.2 pg/mL cut point, higher IL-6 was associated with longer OS benefit in cediranib arms (p intx = .085).
- Higher OPN was associated with shorter OS in the olaparib arm, while lower OPN was associated with longer OS in cediranib arms (p intx = .035).
- Higher PlGF was associated with greater benefit from cediranib for PFS (p intx = .030) and OS (p intx = .024).
Why it matters
These findings suggest that circulating proteins may help distinguish prognosis from treatment-associated benefit in endometrial cancer, including for anti-angiogenic therapy. Such markers could inform future efforts to select or stratify patients, but the reported associations are exploratory and require further evaluation before they can guide treatment decisions.
What to keep in mind
This was a biomarker analysis of baseline samples from 96 participants in a phase 2 trial; the previously established IL-6 cut point did not validate, and the authors state that further evaluation is warranted.